Editorial: Bioresponsive nanomaterials for drug delivery or controlled release.

Front Bioeng Biotechnol

Department of Pharmacology, Institute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University, Beijing, China.

Published: March 2023

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067890PMC
http://dx.doi.org/10.3389/fbioe.2023.1165782DOI Listing

Publication Analysis

Top Keywords

editorial bioresponsive
4
bioresponsive nanomaterials
4
nanomaterials drug
4
drug delivery
4
delivery controlled
4
controlled release
4
editorial
1
nanomaterials
1
drug
1
delivery
1

Similar Publications

Introduction: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer still lacking effective treatment options. Chemotherapy in combination with immunotherapy can restrict tumor progression and repolarize the tumor microenvironment towards an anti-tumor milieu, improving clinical outcome in TNBC patients. The chemotherapeutic drug paclitaxel has been shown to induce immunogenic cell death (ICD), whereas inhibitors of the indoleamine 2,3- dioxygenase 1 (IDO1) enzyme, whose expression is shared in immune regulatory and tumor cells, have been revealed to enhance the anti-tumor immune response.

View Article and Find Full Text PDF

Editorial: Bioresponsive nanomaterials for drug delivery or controlled release.

Front Bioeng Biotechnol

March 2023

Department of Pharmacology, Institute of Systems Biomedicine, Beijing Key Laboratory of Tumor Systems Biology, School of Basic Medical Sciences, Peking University, Beijing, China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!